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ASTHMA
 Rhinoviruses (RVs) are the major cause of acute exacerbations of asthma. 1-3 Human experimental 
RV infection in volunteers with mild asthma is asso-
ciated with augmented physiologic and inﬂ ammatory 
responses to allergen challenge, 4,5 reductions in peak 
expiratory ﬂ ow (PEF) 6 and FEV 1 , 7 and increases in 
bronchial reactivity. 8 In agreement, our own previ-
ously reported study showed that experimental RV16 
infection in asthma induced signiﬁ cant increases in 
bronchial reactivity, lower respiratory tract symptoms, 
and lung function impairment and that signiﬁ cant 
changes in these outcomes did not occur in normal 
subjects. 9 
 Regarding RV-induced airway inﬂ ammation, two pre-
vious studies of experimental RV infection reported 
increases in submucosal CD3 1 lymphocytes and eosin-
ophils in asthmatic and normal groups combined 10 
and in subjects with asthma alone. 11 The increased 
 Background:  The nature of bronchial mucosal inﬂ ammation and its physiologic and clinical signif-
icance in rhinovirus-induced asthma exacerbations is unclear. We investigated bronchial mucosal 
inﬂ ammatory response and its association with physiologic and clinical outcomes in an experi-
mental model of rhinovirus-induced asthma exacerbations. 
 Methods:  We used immunohistochemistry methods to detect phenotypes of inﬂ ammatory cells 
inﬁ ltrating the bronchial mucosa before and after experimental rhinovirus infection in 10 sub-
jects with asthma and 15 normal subjects. 
 Results:  Compared with baseline, rhinovirus infection signiﬁ cantly increased the number of epi-
thelial ( P  5 .005) and subepithelial ( P  5 .017) neutrophils in subjects with asthma only and subepi-
thelial CD68 1 macrophages in both subjects with asthma ( P  5 .009) and normal subjects ( P  5 .018) 
but more so in those with asthma ( P  5 .021). Numbers of CD45 1 , CD68 1 , and CD20 1 cells; 
neutrophils; and eosinophils at day 4 postinfection were positively associated with virus load 
( r  5 0.50-0.72,  P  5 .016-0.03). At acute infection in subjects with asthma, CD4 1 cells correlated 
with chest symptom scores ( r  5 0.69,  P  5 .029), the fall in the 10% fall in FEV 1 (PC 10 ) correlated 
with neutrophils ( r  5  2 0.89,  P  5 .029), the PC 10 correlated inversely with CD4 1 ( r  5  2 0.67,  P  5 .023) 
and CD8 1 cells ( r  5  2 0.65,  P  5 .03), the 20% fall in FEV 1 was inversely associated with CD20 1 cells 
( r  5  2 0.65,  P  5 .03), and higher epithelial CD8 1 cell counts were signiﬁ cantly associated with a 
greater maximum fall in FEV 1 ( r  5  2 0.72,  P  5 .03), whereas higher subepithelial mast cell counts 
were signiﬁ cantly associated with a lower maximum percent fall in peak expiratory ﬂ ow ( r  5 0.8, 
 P  5 .024). 
 Conclusions:  In subjects with asthma, rhinovirus infection induces bronchial mucosal neutrophilia 
and more severe monocyte/macrophage inﬁ ltration than in normal subjects. Airway neutrophils, 
eosinophils, and T and B lymphocytes during infection are related to virus load and physiologic 
and clinical severity, whereas mast cells are related to greater lung function. 
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informed consent, and the study protocol was approved by the 
St. Mary’s NHS Trust Research Ethics Committee (99/BA/345). 
See e-Appendix 1 for other details. 
 Experimental Infection With Human RV16 
 Subjects were administered 10,000 tissue-culture infective dose 
50% of RV16 on day 0 by nasal spray. 9 See e-Appendix 1 for viro-
logic conﬁ rmation of RV16 infection. 
 Bronchoscopy and Clinical Data 
 Bronchial biopsy specimens were taken 14 days before infec-
tion (baseline), at day 4 (acute infection), and at 6 weeks postin-
fection (convalescence). For details about the physiologic and 
clinical data obtained, see e-Appendix 1. 
 Immunohistochemistry 
 CD45 1 pan-leukocyte and inﬂ ammatory cells, eosinophils, neu-
trophils, mast cells, and CD3 1 , CD4 1 , CD8 1 , and CD20 1 cells 
were immunostained using previously described methods. 12 For 
details on the immunostaining method, see e-Appendix 1. 
 Quantiﬁ cation 
 The areas of epithelium and subepithelium in bronchial biopsy 
specimens were assessed using NIH Image, version 1.55 software 
(US National Institute of Mental Health). The inﬂ ammatory cells 
were counted using a light microscope. The data for cell counts 
were expressed as the number of positive cells per square milli-
meter of the subepithelium and per 0.1 mm 2 epithelium. For details 
on the counting methods, see e-Appendix 1. 
 Statistical Analysis 
 Within-group differences in cell counts between baseline 
and infection were assessed with Wilcoxon matched pairs test. 
Mann-Whitney  U test was used to compare differences between 
groups. Spearman rank correlation was used to test for correla-
tions between the numbers of phenotypes of inﬂ ammatory cells 
and physiologic and clinical data.  P  , .05 indicated signiﬁ cance. 
For further details on the statistical analyses, see e-Appendix 1. 
 Results 
 Inﬂ ammatory cells were present in both the bron-
chial epithelial and the bronchial subepithelial com-
partments. Representative photographs are shown in 
 Figures 1A-E . Elastase-positive neutrophils ( Fig 1A ) 
and CD68 1 monocytes/macrophages ( Fig 1B ) appeared 
to be more frequent in the bronchial mucosa of sub-
jects with asthma during acute infection compared 
with baseline ( Figs 1C, 1D ). Application of irrele-
vant antibodies for the inﬂ ammatory cell markers was 
negative ( Fig 1E ). 
 Absolute Counts of Inﬂ ammatory Cells 
 Total Leukocytes:  The  number of subepithelial 
CD45 1 cells in subjects with asthma was signiﬁ cantly 
greater at both baseline ( P  5 .014) and day 4 infection 
( P  5 .025) ( Fig 2A ) than in normal subjects at the 
same time points. Compared with their respective 
number of mucosal CD3 1 cells was accompanied by an 
increase in airway responsiveness and correlated posi-
tively with cold symptoms. 10,11 However, it is unclear 
whether RV-induced bronchial mucosal cellular inﬂ am-
matory responses differ between subjects with and 
without asthma. 
 In this article, we extend our previous work 9 to com-
pare the nature of the bronchial mucosa inﬂ ammatory 
response to experimental RV infection in subjects with 
asthma and in normal healthy subjects and explore 
its physiologic and clinical signiﬁ cance in asthma. We 
hypothesized that the bronchial mucosal cellular 
inﬂ ammatory response to RV infection will be exag-
gerated and of a distinctive predominant inﬂ amma-
tory cell phenotype in subjects with asthma compared 
with normal healthy subjects and that the inﬂ amma-
tory cells recruited to the bronchial mucosa will be 
associated with virus load and increased clinical symp-
toms, airways responsiveness, and airﬂ ow obstruction 
associated with an exacerbation. 
 Materials and Methods 
 Subjects 
 We extended our previously reported investigation of the same 
10 subjects with atopic asthma and 15 subjects without atopic 
asthma ( Table 1 ). 9 These subjects were human RV16 neutralizing 
antibody seronegative. This study was conducted in accordance 
with the amended Declaration of Helsinki. All subjects gave written 
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signiﬁ cantly increased at day 4. At this time point, 
there was a signiﬁ cantly greater number of epithelial 
neutrophils in the subjects with asthma ( P  5 .01) 
( Fig 2B ). EG2 1 eosinophil counts were not signiﬁ -
cantly increased from baseline in either group after 
infection ( Table 2 ). Compared with normal subjects, 
subjects with asthma had a signiﬁ cantly higher number 
of epithelial eosinophils at baseline ( P  5 .011), day 4 
( P  5 .046), and week 6 ( P  5 .01) ( Table 2 ) and showed 
trends toward a greater number of subepithelial 
eosinophils at baseline ( P  5 .07) and day 4 ( P  5 .09), 
baseline and day 4 values, the number of subepithelial 
CD45 1 cells was signiﬁ cantly less at week 6 postin-
fection in both normal subjects ( P  5 .038 and  P  5 .006) 
and subjects with asthma ( P  5 .003 and  P  5 .0006) 
( Fig 2A ). There were no signiﬁ cant differences in counts 
of epithelial CD45 1 cells within and between groups. 
 Granulocytes:  Compared with baseline, the number 
of neutrophils in both epithelium ( P  5 .005) ( Fig 2B , 
 Table 2 ) and subepithelium ( P  5 .017) ( Fig 2C ) of the 
subjects with asthma but not of normal subjects were 
 Figure 1. Immunohistochemistry-stained cells are seen as red fuchsin positivity. A and B, Subject with 
asthma at day 4 rhinovirus 16 infection demonstrating more elastase-positive neutrophils (A) and CD68 1 
monocytes/macrophages (B) in bronchial epithelium and subepithelium. C and D, Subject with asthma 
at baseline showing fewer neutrophils (C) and CD68 1 cells (D). E, Negative control sample shows an 
absence of signal. Scale bar  5 20  m m for all images. 
 Table 1— Baseline Demographic Data 
 Subjects Male (Female) Sex Age, y Serum IgE, U/mL FEV 1 % Predicted Positive Skin Pick Test Histamine PC 20 , mg/mL 
 Normal (n  5 15) 8 (7) 27   2.3 27   8.0 104   3.3 0 20   2.5 
 With asthma (n  5 10) 2 (8) 23   1.4 241   49.8 a 106   4.4 9 3   0.7 a 
 Data are presented as counts or mean   SEM. PC 20  5 20% fall in FEV 1 . 
 a P  , .0001 vs normal (Student  t test). 
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week 6 ( Table 2 ). The number of subepithelial mast 
cells of normal subjects at baseline was unexpectedly 
higher than at day 4 ( P  5 .036) and week 6 ( P  5 .006) 
( Table 2 ). The number of epithelial tryptase-positive 
mast cells was signiﬁ cantly greater in subjects with 
asthma than in normal subjects at day 4 ( P  5 .049) 
and week 6 ( P  5 .01) ( Table 2 ). 
 Lymphocytes:  In subjects with asthma only, the 
number of epithelial CD3 1 cells increased at week 6 
from baseline ( P  5 .023) ( Table 2 ). Unexpectedly, sig-
niﬁ cant decreases in subepithelial CD4 1 counts from 
baseline were seen at week 6 in both normal subjects 
( P  5 .016) and subjects with asthma ( P  5 .013) ( Fig 2E ). 
Compared with normal subjects, subjects with asthma 
had a signiﬁ cantly greater number of subepithelial 
which became statistically signiﬁ cant at week 6 ( P  5 .03) 
( Table 2 ). 
 Macrophages:  Compared with baseline, the num-
ber of subepithelial CD68 1 cells in both normal sub-
jects ( P  5 .018) and subjects with asthma ( P  5 .009) 
were signiﬁ cantly increased at day 4 of acute infec-
tion ( Fig 2D ). There was a signiﬁ cantly greater number 
of subepithelial CD68 1 cells present in subjects with 
asthma than in normal subjects at day 4 ( P  5 .021). No 
signiﬁ cant differences in counts of epithelial CD68 1 
cells were found within and between groups ( Table 2 ). 
 Mast Cells:  There were no signiﬁ cant differences 
within the subjects with asthma in epithelial and sub-
epithelial mast cell counts from baseline to day 4 or 
 Figure 2. Cell counts in bronchial biopsy specimens of subjects with and without asthma at baseline 
and days 4 and 6 of rhinovirus 16 infection. A, CD45 1 cells. B, Epithelial neutrophils. C, Subepithelial 
neutrophils. D, CD68 1 cells. E, CD4 1 cells. Data are presented as the number of positive cells per 
square millimeter of subepithelium or per 0.1 mm 2 of epithelium.  and   show individual counts, and 
horizontal bars show median values (Wilcoxon matched pairs and Mann-Whitney  U tests). 
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 Clinical Symptoms and Airway Hyperresponsive-
ness:  At day 4, epithelial CD4 1 counts in subjects with 
asthma correlated with total chest symptom scores 
recorded during the 2-week postinfection period 
( r  5 0.69,  P  5 .029) ( Fig 5A ). Those with high subepi-
thelial neutrophil counts had a signiﬁ cantly larger fall 
in the 10% fall in FEV 1 (PC 10 ) from baseline to day 6 
postinfection ( r  5 0.89,  P  5 .029) ( Fig 5B ). The PC 10 
at day 6 correlated inversely with subepithelial CD3 1 
( r  5  2 0.81,  P  5 .016) ( Fig 5C ), CD4 1 ( r  5  2 0.67, 
 P  5 .023) ( Fig 5D ), and CD8 1 ( r  5  2 0.65,  P  5 .03) 
( Fig 5E ) cells, and the 20% fall in FEV 1 at day 6 was 
inversely associated with subepithelial CD20 1 cells 
( r  5  2 0.65,  P  5 .03) ( Fig 5F ). 
 Lung Function:  At day 4, higher epithelial CD8 1 cell 
counts in subjects with asthma were signiﬁ cantly asso-
ciated with a greater maximum fall in FEV 1 (percent 
fall from baseline) ( r  5  2 0.72,  P  5 .03) ( Fig 6A ). Of 
interest, higher subepithelial mast cell counts were 
signiﬁ cantly associated with a lower maximum percent 
fall in PEF ( r  5 0.8,  P  5 .024) ( Fig 6B ). In all subjects 
at day 4, higher epithelial ( r  5 0.64,  P  5 .03) and sub-
epithelial ( r  5  2 0.53,  P  5 .01) CD4 1 cell counts were 
signiﬁ cantly associated with a greater maximum fall 
in FEV 1 . 
 Serum IgE:  The levels of serum IgE were signiﬁ -
cantly correlated with subepithelial EG2 1 eosinophils 
in normal subjects at day 4 ( r  5 0.64,  P  5 .017) and 
in subjects with asthma at both baseline ( r  5 0.94, 
 P  5 .005) and day 4 ( r  5 0.83,  P  5 .013) ( Figs 7A, 7B ). 
CD4 1 cells at baseline ( P  5 .043). There were no sig-
niﬁ cant differences in epithelial CD4 1 , CD8 1 , or 
CD20 1 cell counts and in subepithelial CD3 1 , CD8 1 , 
or CD20 1 cell counts in either group after infection 
( Table 2 ). 
 Changes in Numbers of Inﬂ ammatory Cells 
 To investigate differences in inﬂ ammatory responses 
of subjects with and without asthma to RV infection, 
the magnitude of the changes of inﬂ ammatory cell 
counts from baseline to infection was compared. The 
changes in numbers of both epithelial ( P  5 .0036) 
and subepithelial ( P  5 .018) neutrophils from base-
line to day 4 infection in subjects with asthma were 
signiﬁ cantly greater than those in normal subjects 
( Figs 3A, 3B ). The changes in subepithelial CD68 1 
cell counts from baseline to day 4 infection in sub-
jects with asthma were also signiﬁ cantly greater than 
those in normal subjects ( P  5 .025) ( Fig 3B ). No sig-
niﬁ cant differences with respect to changes in num-
bers of other inﬂ ammatory cell phenotypes were seen 
between groups from baseline to day 4 or week 6. 
 Associations 
 Virus Load:  In all subjects at day 4, the number of 
subepithelial CD45 1 cells was associated with peak 
sputum virus load ( r  5 0.5,  P  5 .025) ( Fig 4A ), and 
subepithelial neutrophils ( r  5 0.62,  P  5 .027) ( Fig 4B ), 
EG2 1 eosinophils ( r  5 0.64,  P  5 .016), and CD68 1 cells 
( r  5 0.65,  P  5 .016) ( Fig 4C ) correlated with BAL virus 
load. 
 Table 2— Counts of Phenotype of Inﬂ ammatory Cells Inﬁ ltrating Epithelial and Subepithelial Areas in Bronchial 
Mucosa of Subjects With and Without Asthma 
 Asthma Normal 
 Group and Cells Baseline D 4 Wk 6 Baseline D 4 Wk 6 
 Epithelium  
 CD45 1 126 (41-434) 164 (93-1,600) 111 (62-597) 109 (42-254) 152 (84-394) 113 (27-205) 
 Neutrophil elastase positive 4.9 (0-12) 16.1 a (4-50) 2.6 (0-28) 5.2 (0-23) 6 (0-24) 5 (6-67) 
 EG2 1 8.4 b (0-160) 2.4 c (0-53) 1.2 d (0-4) 0 (0-8) 0 (0-9) 0 (0-2) 
 Tryptase positive 6 (0-15) 7 c (0-16) 11 d (3-24) 2 (0-41) 2 (0-7) 5 (0-13) 
 CD68 1 14 (3-67) 28 (1-640) 24 (7-70) 22 (0-78) 30 (5-93) 36 (4-133) 
 CD3 1 88 (20-145) 104 (44-452) 100 a (81-393) 97 (40-187) 99 (38-239) 125 (34-267) 
 CD4 1 13 (2-38) 15 (3-65) 10 (2-55) 11 (0-26) 7 (1-35) 5 (0-27) 
 CD8 1 64 (11-194) 80 (23-321) 77 (48-186) 79 (3-152) 70 (20-148) 76 (17-134) 
 CD20 1 2 (0-7) 1 (0-4) 1 (0-3) 0 (0-12) 1 (0-15) 0 (0-2) 
 Subepithelium  
 EG2 1 84 (0-572) 55 (4-717) 26 d (1-133) 18 (0-214) 9 (0-202) 5 (0-50) 
 Tryptase positive 142 (78-252) 121 (8-285) 95 (16-243) 183 c,d (81-342) 92 (20-335) 58 (16-290) 
 CD3 1 803 (292-1,280) 587 (159-2,127) 458 (241-1,406) 527 (225-1,091) 434 (91-1,261) 440 (99-1,373) 
 CD8 1 712 (129-1,451) 536 (120-2,354) 457 (136-1,103) 407 (155-792) 418 (114-1,003) 306 (41-623) 
 CD20 1 53 (17-322) 88 (15-351) 71 (10-275) 51 (0-386) 58 (4-379) 14 (0-98) 
 Data are presented as median (range) of positive cell counts per 0.1 mm 2 epithelium and per square millimeter subepithelium. 
 a P  5 .005 and .023 vs asthma at baseline, respectively. 
 b P  5 .011 vs normal at baseline. 
 c P  5 .036, .046, and .049 vs normal on d 4, respectively. 
 d P  5 .006, .01, and .03 vs normal at wk 6, respectively. 
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been related to clinical severity. 14 Increased numbers 
of neutrophils have been detected in the bronchial 
mucosa of subjects with severe asthma experiencing 
naturally occurring exacerbations. 15 To our knowledge, 
however, no attempt has been made to determine 
whether RV infection alone can initiate bronchial 
mucosal neutrophilia, and its physiologic and clinical 
outcomes are unknown. 
 We reported in a previous publication on the clin-
ical study from which the present biopsy specimens 
were collected increased numbers of BAL eosino-
phils during acute infection in the asthmatic group 
relative to the normal group, with similar, but nonsig-
niﬁ cant trends for neutrophils. 9 However, signiﬁ cant 
increases in BAL or induced sputum inﬂ ammatory 
cells from baseline to acute RV infection within the 
asthma group were not detected. Consistent with the 
BAL results, we found increased epithelial eosinophil 
and neutrophil counts in subjects with asthma vs nor-
mal subjects during acute RV infection. In addition, 
we demonstrated signiﬁ cant increases in the number 
of both epithelial and subepithelial neutrophils from 
baseline to acute infection in the asthma group, which 
were signiﬁ cantly higher than that in the normal group. 
We did not ﬁ nd increased numbers of neutrophils 
at week 6, which suggests that virus-induced airway 
neutrophilic inﬂ ammation in patients with mild asthma 
occurs only during the virus-induced acute asthma 
exacerbation and not during convalescence. Thus, 
in contrast to normal subjects, acute experimental 
RV16 infection selectively increases bronchial mucosal 
neutrophils in atopic asthma, and the higher numbers 
of neutrophils are related to the severity of infection 
and airway hyperresponsiveness. These data suggest 
that virus infection is one of the major etiologies 
inducing neutrophilic asthma. Because neutrophils 
play an important role in innate immune responses to 
clear virus, they can cause destruction of lung tissues 
through release of their proteases and other media-
tors. 16 Therefore, the balance between the protective 
and pathologic effects of neutrophils in the course 
of virus-induced asthma exacerbations needs to be 
clariﬁ ed when drug treatment to control neutrophilic 
inﬂ ammation 17 is studied in the future. 
 Whereas we consider that asthma severity and 
treatment affect the magnitude of the inﬂ ammatory 
response to RV infection, the nature of the inﬂ am-
mation is more inﬂ uenced by the time at which the 
biopsy specimens are taken in relation to the onset of 
RV infection. With respect to the latter, we believe 
that the results should not have been affected by the 
subjects with mild asthma studied who had not taken 
inhaled or oral corticosteroids. 
 The effect of RV infection on sputum and BAL 
CD68 1 cells in subjects with and without asthma was 
not investigated in our previously reported study. 9 
There were no signiﬁ cant associations between serum 
IgE level and other phenotypes of inﬂ ammatory cells. 
 Discussion 
 We demonstrated that compared with normal sub-
jects, subjects with asthma and RV infection had an 
exaggerated bronchial mucosal inﬂ ammatory response 
particularly characterized by increased numbers of 
neutrophils and CD68 1 monocytes/macrophages. Sig-
niﬁ cant correlations were found between CD45 1 cells, 
neutrophils, and CD68 1 cells and virus load and between 
neutrophils and T and B lymphocytes and airway 
hyper responsiveness, chest symptoms, and reduced 
lung function, whereas mast cells were related to better 
lung function. 
 Previous experimental studies have shown that 
RV16 infection is associated with a signiﬁ cant increase 
in peripheral blood and BAL neutrophil counts in 
allergic asthma. 13 In sputum, virus infection in asthma 
exacerbations has been associated with increased num-
bers of neutrophils and elevation of both neutrophil 
and eosinophil degranulation products, and cell lysis has 
 Figure 3. A and B, Changes in counts of epithelial (A) and sub-
epithelial (B) neutrophils and CD68 1 cells from baseline to d 4 
postinfection in bronchial biopsy specimens from subjects with 
and without asthma. Data are presented as change in the number 
of positive cells per 0.1 mm 2 of epithelium or per square milli-
meter of subepithelium.   and   show individual changes in 
counts, and horizontal bars show median values (Mann-Whitney 
 U test). 
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not ﬁ nd a difference in the number of tryptase-positive 
mast cells in the bronchial mucosa between subject 
groups at baseline, which is consistent with these pre-
vious reports. 24,25 Although there were no changes in 
numbers of epithelial mast cells within either group 
during RV infection, we detected a greater number 
of epithelial mast cells in asthma day 4 and week 6 
compared with normal day 4 and week 6, implying that 
asthma susceptibility to immediate aller gic response 
could be greater after RV infection. The numbers of 
subepithelial mast cells declined between baseline and 
acute infection and further declined between acute 
infection and convalescence in normal subjects. This 
ﬁ nding appears to be inconsistent with an earlier study 
in which the number of tryptase-positive mast cells in 
bronchial submucosa declined between the infection 
and convalescent periods, but no initial increase was 
seen between baseline and infection. 26 Of note, we 
detected in the present study that in subjects with 
asthma, those with the highest subepithelial mast cell 
counts had the lowest maximum percent falls in PEF 
during acute infection. In this regard, the ﬁ ndings 
support the results described previously in which the 
numbers of mast cells in severe asthma correlated with 
better rather than worse lung function, suggesting 
that recruitment of mast cells, particularly to the dis-
tal lung, may be protective for lung function in severe 
asthma. 27 
Seymour et al 18 reported an increase in the number 
of macrophages seen in bronchial biopsy specimens 
of normal subjects in response to experimental RV16 
infection, but subjects with asthma were not investi-
gated. In contrast, the present study shows that acute 
RV infection increases the number of subepithelial 
CD68 1 cells of subjects with and without asthma. 
Notably, the changes in levels observed in the asthma 
group from baseline to acute infection were signiﬁ -
cantly greater than those in the normal group. Other 
work has suggested that impaired macrophage pro-
duction of T-helper 1-related cytokines is strongly 
implicated in asthma exacerbation pathogenesis. 19,20 
Therefore, further investigation is needed to dis-
cern their role in asthma exacerbations induced by 
RV infection. 
 Airway mast cells are key in the immediate aller-
gic response and are long associated with the path-
ogenesis of stable asthma. 21,22 Using chloroacetate 
esterase to identify lysosomal granules in mast cells, 
Lozewicz et al 23 found increased mast cell numbers 
in endobronchial biopsy specimens from subjects 
with atopic asthma compared with normal subjects. 
However, the numbers of tryptase-positive mast cells, 
tryptase-positive and chymase-negative mast cells, and 
tryptase- and chymase-positive mast cells in bronchial 
mucosa of subjects with symptomatic atopic asthma 
was not greater than that in normal subjects. 24,25 We did 
 Figure 4. A-C, Correlations between the numbers of subepithelial CD45 1 cells (A) at d 4 and peak 
sputum virus load at d 3 after infection and neutrophils (B) and CD68 1 cells (C) at d 4 and BAL virus 
load at d 4 in all subjects with asthma (  ) and normal subjects (  ) (Spearman rank correlation). 
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the involvement of both T and B lymphocytes in the 
severity of asthma exacerbations induced by virus 
infection. The absence of increased counts of CD3 1 
and CD8 1 T lymphocytes on day 4 of acute RV infec-
tion in subjects with asthma alone is not in keeping 
with increased subepithelial CD3 1 and CD8 1 cells at 
day 6 reported previously. 11 This inconsistency may 
be due to differences in timing of the biopsies, as the 
present specimens were taken at day 4 vs day 6. The 
reductions in subepithelial CD4 1 counts from baseline 
to convalescence may be due to a decrease in blood 
CD4 1 cell counts during acute infection, 9 which could 
be a result of less recruitment of CD4 1 cells into the 
lung. 
 IgE plays a critical role in eosinophil recruitment into 
the airways after antigen provocation. 29 Zambrano et al 30 
demonstrated that patients with mild asthma with 
 The biologic mechanism for a protective role 
remains unclear. Rauter et al 28 notably demonstrated 
that  b -tryptase, a major protease released during mast 
cell activation, cleaves IgE. They suggested that IgE 
cleavage by effector cell proteases is a natural mech-
anism for controlling allergic inﬂ ammation. The role 
of mast cells in the pathogenesis of virus-induced asthma 
exacerbations clearly merits further study. 
 We demonstrate for the ﬁ rst time, to our knowledge, 
in subjects with asthma that epithelial CD4 1 cell 
counts at day 4 of infection correlates with total chest 
symptom scores, and the number of bronchial mucosal 
CD3 1 , CD4 1 , and CD8 1 T and CD20 1 B lympho-
cytes are associated with increased airway hyperre-
sponsiveness. Additionally, the subjects with asthma 
with high epithelial CD8 1 counts had signiﬁ cantly 
greater maximum falls in FEV 1 . The ﬁ ndings suggest 
 Figure 5. A-F, In subjects with asthma alone, correlations between total chest symptom score d 0 to 14 
after the rhinovirus 16 infection period and counts of epithelial CD4 1 cells (A), between fall in PC 10 
(log 2 ) and counts of subepithelial neutrophils at d 4 (B), between PC 10 at d 6 and counts of subepithelial 
CD3 1 (C), CD4 1 (D), and CD8 1 (E) cells at d 4; and between PC 20 at d 6 and counts of subepithelial 
CD20 1 cells at d 4 (F) (Spearman rank correlation, n  5 10 for all). PC 10  5 10% fall in FEV 1 ; PC 20  5 20% 
fall in FEV 1 . 
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Another study showed no difference in changes of 
bronchial mucosa inﬂ ammatory cell counts between 
normal subjects and subjects with atopic rhinitis experi-
encing naturally occurring common cold virus infec-
tion. 34 However, to answer this question directly, 
bronchial mucosa inﬂ ammatory responses to experi-
mental RV16 infection in subjects with atopy but not 
asthma requires further investigation. 
 We also acknowledge that we have investigated rel-
atively small numbers of subjects, albeit in some detail, 
and that a large number of statistical tests were car-
ried out; thus, the study may have failed to detect some 
genuine observations due to limitations of statistical 
power. However, we consider its strengths to include 
the comprehensive and meticulous immunochemical 
approach and rigorous design of the human challenge 
model, permitting accurate sampling before and dur-
ing infection of a uniform nature and known time of 
onset. Despite these caveats, novel data and interesting 
observations have emerged. 
 In conclusion, RV16 infection induced a more severe 
neutrophil and monocyte/macrophage-rich inﬂ am-
matory response in the bronchial mucosa of subjects 
high levels of IgE had signiﬁ cantly greater lower respi-
ratory tract symptom scores during the initial 4 days 
of infection than those with low IgE levels. These 
patients also had higher total blood eosinophil counts 
at baseline. Building on these ﬁ ndings, we demon-
strate that subjects with asthma with high levels of 
serum IgE at both baseline and day 4 have signiﬁ -
cantly greater numbers of submucosal EG2 1 eosino-
phils. These ﬁ ndings imply that patients with atopic 
asthma with high levels of serum IgE could have more 
EG2 1 eosinophils in their airway and experience more 
severe illness during acute RV infection. Anti-IgE 
therapy, 31,32 therefore, may be useful for preventing 
exacerbations of asthma triggered by RV infection. 
 We acknowledge that an atopic nonasthma group 
was not included in the present study. Thus, the dif-
ferences observed between the normal and asthma 
groups may have been partly due to changes attribut-
able to atopy vs asthma. Previous work reported that 
compared with normal subjects without atopy, nasal 
biopsy specimens of subjects with atopy during experi-
mental RV16 infection did not show increases in inﬁ l-
tration of inﬂ ammatory cells (including neutrophils). 33 
 Figure 6. A, B, In subjects with asthma at d 4 after rhinovirus infection, correlations between max-
imum fall in FEV 1 (%) and counts of epithelial CD8 1 cells (A) and between maximum fall in PEF (%) 
and counts of subepithelial tryptase-positive mast cells (B) (Spearman rank correlation). PEF  5 peak 
expiratory ﬂ ow. 
 Figure 7. A, B, Correlations between serum IgE levels and counts of subepithelial EG2 1 eosinophils in 
asthma at baseline (A) and d 4 after rhinovirus infection (B) (Spearman rank correlation). 
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